Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
A Japanese health ministry panel on March 2 recommended approvals for Daiichi Sankyo’s measles-mumps-rubella (MMR) vaccine, Haihe Biopharma’s PI3Kα inhibitor risovalisib, and MSD’s once-daily HIV combination doravirine/islatravir. The Pharmaceutical Affairs Council’s Second Committee on Drugs endorsed three new molecular entities…
To read the full story
Related Article
- Daiichi Sankyo Wins Japan Approval for MMR Vaccine Mimrit
May 12, 2026
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- Japan OKs Bayer’s MRI Agent, Haihe’s PI3Kα Med, Enhertu’s Tumor-Agnostic Use, and More
March 24, 2026
- Japan Hands Out Orphan Tags to Ianalumab, Bleximenib, and Lots More Drugs
March 23, 2026
- Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
- Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
February 24, 2026
- Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned
January 23, 2026
- Taiho Bags Haihe’s PI3Kα Inhibitor Risovalisib
October 17, 2025
- MSD Files for Japan Approval of Once-Daily HIV Combo Pill
July 14, 2025
- Pfizer Seeks Wider Label for PARP Inhibitor Talzenna in Japan
May 8, 2025
- Paxlovid Filed for Pediatric Label Expansion in Japan: Pfizer
May 1, 2025
- Sanofi’s Dupixent Filed for Bullous Pemphigoid in Japan
April 28, 2025
- Gilead Files Trodelvy for HR+/HER2- Breast Cancer in Japan
April 25, 2025
- Enhertu Filed for HER2 Positive Solid Tumors in Japan
April 25, 2025
- Xocova Filed for Post-Exposure Prophylaxis for COVID-19 in Japan
March 28, 2025
- Daiichi Sankyo Files MMR Vaccine in Japan
March 26, 2024
REGULATORY
- Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
- MHLW Gives Kissei until July 21 to Report on Tavneos
July 3, 2026
- Centrist Reform Alliance Warns US MFN Policy Poses “Real Crisis” for Drug Access
July 3, 2026
- Ishin Urges Govt to Make Healthcare, Drug Innovation Core Growth Strategy
July 3, 2026
- MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…